SCHEMBL7201243

SCHEMBL7201243

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3ccncc3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 3/20 0.36
DPP4 P27487 2/20 0.35
CCR6 P51684 2/20 0.35
UCHL1 P09936 1/20 0.34
USP30 Q70CQ3 1/20 0.34
GPR119 Q8TDV5 1/20 0.34
DPP7 Q9UHL4 1/20 0.34
F10 P00742 1/20 0.34
FASN P49327 2/20 0.33
CCR7 P32248 1/20 0.33
GHSR Q92847 1/20 0.33
NAMPT P43490 1/20 0.33
IKBKB O14920 1/20 0.33
CHUK O15111 1/20 0.33
IKBKE Q14164 1/20 0.33
CDC7 O00311 1/20 0.33
CDK9 P50750 1/20 0.33
USP2 O75604 1/20 0.32
CYP3A4 P08684 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201014 0.90 SMN1; SMN2 (0.41) MMP13GHSRSMN1; SMN2MMP1
SCHEMBL7292210 0.89 GHSR (0.46) DPP4CCR6UCHL1USP30GPR119
SCHEMBL7203051 0.89 MMP1 (0.39) MMP13SMN1; SMN2MMP1
SCHEMBL7300738 0.88 MMP13 (0.48) MMP13CYP2C19MMP1
SCHEMBL7204066 0.88 ALDH1A1 (0.38) MMP13MMP1
SCHEMBL7201540 0.88 ADAMTS4 (0.39) MMP13DPP4MMP1
SCHEMBL7202625 0.85 CCR6 (0.39) MMP13DPP4CCR6DPP7F10
SCHEMBL7203105 0.85 MMP13 (0.38) MMP13DPP4GPR119DPP7MMP1
SCHEMBL7205455 0.85 MMP9 (0.44) MMP13SMN1; SMN2MMP1
SCHEMBL7202584 0.84 RORC (0.46) MMP13GPR119F10MMP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP13 4/4885DPP4 2594/4885CCR6 276/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.